Pathophysiology of idiopathic gastroparesis and implications for therapy by Bekkelund, Mattis et al.
Pathophysiology of Idiopathic Gastroparesis and Implications for Therapy 
Mattis Bekkelund1,2, Dag A. Sangnes2,3,4, Jan Gunnar Hatlebakk2,3,4, Lars 
Aabakken1,5 
1Faculty of Medicine, Department of Clinical Medicine, University of Oslo, Oslo, Norway; 
2National Centre for Functional Gastrointestinal Disorders, Department of Medicine, 
Haukeland University Hospital, Bergen, Norway; 3Department of Medicine, Haukeland 
University Hospital, Bergen, Norway; 4Clinical institute 1, University of Bergen, Bergen, 
Norway; 5Department of Transplantation Medicine, Section for Gastroenterology, Oslo 




Faculty of Medicine, Department of Clinical Medicine, University of Oslo, Oslo, Norway 
Haakon den godes vei 29  
0373, Oslo 
Tel: +47 48186897 
Email: mattis.bekkelund@studmed.uio.no 
 









Idiopathic gastroparesis is a gastric motility disorder characterized by chronic upper 
gastrointestinal symptoms and delayed gastric emptying without an identifiable underlying 
condition. This review summarizes recent understanding of the pathophysiology and 
treatment of idiopathic gastroparesis 
 
Materials and methods 
Structured literature search in the PubMed, Embase and ClinicalTrials.gov databases 
 
Results 
Idiopathic gastroparesis involves several alterations in gastric motility and sensation, 
including delayed gastric emptying, altered myoelectrical activity, impaired fundic 
accommodation, visceral hypersensitivity and disturbances in antropyloroduodenal motility 
and coordination. Multiple cellular changes have been identified, including depletion of 
interstitial cells of Cajal (ICC) and enteric nerves, as well as stromal fibrosis. The underlying 
cause of these changes is not fully understood, but may be an immune imbalance, including 
loss of anti-inflammatory heme-oxygenase-1 positive (HO-1) macrophages. There is currently 
no causal therapy for idiopathic gastroparesis. The treatment ladder consists of dietary 
measures, prokinetic and antiemetic medications, and varying surgical or endoscopic 
interventions, including the promising pyloric therapies. There are ongoing trials with several 
novel medications, raising hopes for future treatment. 
 
Conclusions 
Patients with idiopathic gastroparesis presents several pathophysiological alterations in the 
stomach, where depletion of ICC is of special importance. Treatment is currently focused on 
alleviating symptoms through dietary adjustments, medication or surgical or endoscopic 
interventions. 
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Gastroparesis is a chronic disorder in which gastric emptying is delayed without mechanical 
obstruction or other underlying conditions [1, 2]. The main subsets of gastroparesis are 
idiopathic gastroparesis, diabetic gastroparesis and iatrogenic gastroparesis due to surgery or 
medication [1]. Idiopathic gastroparesis is assumed to be a heterogeneous group of hitherto not 
defined etiologies, and the diagnosis can be made when no other underlying cause of 
gastroparesis is identified. Idiopathic gastroparesis makes up 36-65% of patients with 
gastroparesis; however, estimates are uncertain [3-5]. Significantly more women than men are 
affected, and female gender has been linked to increased symptom severity [3, 4, 6].  
The onset of gastroparesis symptoms may be acute or insidious, and symptoms may 
progress in different patterns: Stable, intermittent exacerbations or gradually worsening 
symptom load [5, 6]. Early satiety, postprandial fullness, bloating, nausea, and vomiting are 
considered the cardinal symptoms of gastroparesis [7]. Other symptoms such as upper or 
lower abdominal pain, gastroesophageal reflux symptoms, anorexia, constipation and diarrhea 
are also common [3-6, 8, 9]. No single symptom or symptom cluster reliably differentiates the 
different subsets of gastroparesis, and the association between gastric retention and symptom 
severity in gastroparesis is weak [10]. The demarcation of idiopathic gastroparesis in relation 
to functional dyspepsia is also unclear, as there is a substantial overlap in symptoms and 
gastric motility dysfunctions, including delayed gastric emptying.   
The pathophysiology of idiopathic gastroparesis remains poorly understood and as a 
consequence, development of new therapeutic modalities has been slow. However, an increased 
interest in gastroparesis combined with new technologies for assessing gastrointestinal motility, 
has led to increased insight into the topic. In this article, we review the literature on the 
pathophysiology of idiopathic gastroparesis, and its potential therapeutic implications.  
 
Materials and methods 
Two structured searches in the databases of PubMed and Embase was performed using the 
search strings ‘(idiopathic gastroparesis) AND (pathophysiology OR pathology OR 
symptoms)’ and ‘(idiopathic gastroparesis) AND (therapy OR treatment)’. The first search 
yielded 245 hits in PubMed and 97 hits in Embase. The second search yielded 199 hits in 
PubMed and 79 hits in Embase. Only review articles and original articles were included in the 
search. The search was not time-limited and ended 16.8.18. After removal of duplicates, articles 
were initially evaluated based on title relevance. The full text of the remaining articles was then 
assessed, and articles deemed not relevant for this review were excluded. 34 articles were 
included from other article reference lists. This left us with 107 articles included in this review. 
See flow chart in Figure 1 for further details on article selection. To get an overview of ongoing 
therapeutic trials, we also performed a structured search in the ClinicalTrials.gov database using 
the search string “idiopathic gastroparesis”. The search was performed on October 2, 2018 and 
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Insight in the cellular pathology of idiopathic gastroparesis is crucial to understand the 
pathophysiology behind impaired gastric motility, symptom generation and for the 
development of new therapies. However, as full-thickness biopsies of the stomach are mainly 
acquired laparoscopically during insertion of a gastric electrical stimulator, results are currently 
applicable only to patients with severe symptoms refractory to medical therapy. Therefore, the 
cellular pathology of mild and moderate gastroparesis is largely unknown. 
Histopathological studies of gastric full-thickness biopsies have consistently revealed a 
loss of interstitial cells of Cajal (ICC) in the gastric body, antrum and pylorus in patients with 
refractory idiopathic gastroparesis [11-18]. Further, in transmission electron microscopy 
(TEM) studies, ICCs show marked morphological changes indicative of injury such as few or 
swollen mitochondria, and a loss of contact with nerves and smooth muscle cells and adjacent 
ICCs [13, 19]. Given the physiological role of ICCs in mechanotransduction and initiation and 
propagation of slow waves, absence of ICCs could be central in the pathophysiology of 
idiopathic gastroparesis [20]. Still, it is not fully understood whether depletion of ICCs 
correlates with symptom severity in idiopathic gastroparesis [11, 12, 14]. 
Another prominent ultrastructural feature in idiopathic gastroparesis is the presence of 
fibrosis in the stroma, which is significantly increased in comparison with diabetic gastroparesis 
[19]. Fibrillary sheaths encase smooth muscle cells, ICCs and particularly nerve endings [13, 
19]. It has been speculated that these fibrillary sheets may impair smooth muscle metabolism 
and as such cause cell damage [19]. The nerve structures themselves also have pathological 
features. On examination with TEM, both nerve endings and neuronal bodies seem to have 
altered morphology with abnormal mitochondria, chaotically arranged neurofilaments and 
nerve endings empty of granulae, indicating a loss of neurotransmitter [13, 19]. Additionally, 
some studies by light microscopy, hematoxylin and eosin-staining and immunohistochemistry 
have found a loss of enteric nerve bodies and fibers [13, 15, 16, 21]. Patients with idiopathic 
gastroparesis may also have decreased levels of neurotransmitters such as NO and Substance P 
[13, 16]. However, these results are uncertain and in one study, NOS1-expression was found to 
be higher than in controls [22].  
In studies of antral full-thickness biopsies, patients with idiopathic gastroparesis show 
a loss of M2-like macrophages with an anti-inflammatory phenotype within the muscular wall 
[23]. Macrophages are thought to play a central role in diabetic gastroparesis, in which a loss 
of anti-inflammatory heme-oxygenase-1 (HO-1) positive macrophages leads to decreased 
protection against oxidative stress, resulting in damage to ICCs and delayed gastric emptying 
in diabetic mice [24-27]. A role for macrophages and HO-1 in idiopathic gastroparesis is now 
starting to emerge. Longer alleles of repeat polymorphisms of the gene coding for HO-1 has 
been found to be associated with nausea severity [28].  Further, expression of HMOX1, a 
marker for HO-1 is decreased in the gastric muscularis externa [22]. An increase in 
expression of genes associated with inflammatory M1-like macrophages along with other 
immune imbalances has also been found by Grover et al [29]. As such, a loss of HO-1 
expressing M2-like macrophages could be a mechanism leading to the oxidative damage seen 
in idiopathic gastroparesis.  
Abnormalities in smooth muscle cell contractile elements and markers of contractility 
has been demonstrated in idiopathic gastroparesis, suggesting that in a subset of patients, 
impaired motility may stem from impaired contractility of smooth musculature [22]. However, 
the majority of smooth muscle cells show no pathological alterations on TEM [19]. As such, 
the role of smooth muscle cells in idiopathic gastroparesis is not fully understood.  
Other cell types that may be of importance also seem to be altered in idiopathic 
gastroparesis. On examination with TEM, enteric glial cells show signs of pathological 
alterations and the cytoplasm is filled with lysosomes, lipofuscinic bodies and vacuoles [13, 
19]. This may be another distinguishing feature of idiopathic gastroparesis, as enteric glial cell 
damage has not been observed in diabetic gastroparesis. Telocytes (Platelet-derived growth 
factor receptor α+ fibroblast-like cells), a recently identified cell type believed to play a role in 
slow wave conduction, neural transduction and gastric pacemaker activity, may also play a part 
in idiopathic gastroparesis. No changes in telocyte number has been found when examined by 
immunolabelling [30]. However, one study examining transcriptional changes in idiopathic 
gastroparesis found a loss of mRNA encoding for PDGFRα in all samples, suggesting a loss of 
telocytes in idiopathic gastroparesis [22]. This was associated with a loss of platelet-derived 
growth factor-B (PDGFB), a ligand for PDGFRα, implicating a role for PDGFB in the 
maintenance of the gastric telocyte-population and an impairment of this mechanism in 
idiopathic gastroparesis. 
 
Gastric myoelectrical activity 
Altered gastric myoelectrical activity seems to be a common feature in idiopathic gastroparesis 
when measured by electrogastrography (EGG) [31-33] and serosal recording techniques [31, 
34].  
 Using a dense array of serosal electrodes able to detect alterations in spatial 
coordination and propagation of slow waves, O’Grady and colleagues discovered multiple 
novel types of dysrhythmias in patients with idiopathic gastroparesis [34]. An important 
finding was that patients with apparently normal slow wave frequency also have altered 
myoelectrical activity. Feelings of nausea have been linked to EGG alterations and such 
alterations have been proposed as an objective marker of nausea [35]. As such, gastric 
dysrhythmia may be a mechanism specifically related to nausea and thereby a central feature 
of idiopathic gastroparesis. Further, successful medical therapy for idiopathic gastroparesis 
was associated with normalization of EGG parameters in one study [36].  
The underlying mechanisms leading to aberrant slow-wave activity in gastroparesis is 
not well understood. However, a low ICC-count is associated with dysrhythmia in gastroparesis 
and its physiological roles in slow wave initiation and conduction makes ICCs likely to be 
central in the pathogenesis of dysrhythmias [12, 34]. Given the role of fibrosis in cardiac 
arrhythmias, the fibrosis seen in idiopathic gastroparesis may play a similar role.  
 
Motility disturbances 
Delayed gastric emptying 
Delayed gastric emptying is mandatory for the diagnosis of gastroparesis [1]. However, the 
pathophysiological mechanisms behind delayed gastric emptying in idiopathic gastroparesis is 
not clear. In a study assessing the reproducibility of gastric emptying scintigraphy (GES) in 
patients with upper gastrointestinal symptoms, delayed gastric emptying of solids seem to be 
a relatively stable parameter, though the authors noted that for mild gastroparesis, repeated 
testing may be necessary to confirm delayed gastric emptying [37].  
There is consensus that gastric emptying scintigraphy of solids is the most accurate 
method to diagnose gastroparesis [38]. However, in a subset of patients, gastric emptying of 
solids may be normal whilst gastric emptying of liquids is impaired [39-41]. Isolated delayed 
liquid emptying may be more common in non-diabetic gastroparesis [39].  
The association between the degree of gastric retention and loss of ICCs in the gastric 
body is uncertain [12, 14, 15, 23]. However, pyloric fibrosis and ICC-loss may be more 
common in gastroparesis than in the so-called gastroparesis-like syndrome, in which the 
patient experiences symptoms of gastroparesis but without delayed gastric emptying [18]. As 
such, pyloric fibrosis and ICC-loss may be a mechanism behind delayed gastric emptying. 
The relationship between delayed gastric emptying of solids and symptom generation 
in idiopathic gastroparesis is uncertain. No specific symptoms have been found to consistently 
correlate with the severity of gastric retention [6, 42-44]. However, in a multicenter study of 
243 patients with idiopathic gastroparesis, severe gastric retention (>35%) after 4 hour GES 
was associated with a higher score on the global Gastroparesis Cardinal Symptom Index [6, 
7]. 
 
Interdigestive motor activity 
Gastric emptying time (GET) may be assessed by a wireless motility capsule (SmartPill®, 
Medtronic, Minneapolis, USA) measuring pH, pressure and temperature throughout the 
gastrointestinal tract. Being a non-digestible capsule, one assumes that expulsion of the 
SmartPill from the stomach is caused by interdigestive phase III contractions [45]. As such, 
GET differs from GES in the mechanism of gastric emptying that is measured. When 
measured with SmartPill, a subset of patients with idiopathic gastroparesis appears to have a 
delayed interdigestive phase III, with migrating motor complexes re-appearing 5 hours or 
more postprandially [46-49]. Though scarcely studied, impaired motilin release may be 
associated with the delay or absence of interdigestive phase III contractions in idiopathic 
gastroparesis [50].  
 
Impaired fundic accommodation 
In impaired fundic accommodation (FA), the gastric fundus fails to exert its reservoir function 
after the ingestion of food or drink. Impaired gastric accommodation has been reported to be 
associated with early satiety and anorexia [44, 51]. The gold standard for measuring fundic 
accommodation is currently the gastric barostat: An infinitely compliant balloon which is 
placed in the proximal stomach to measure changes in the volume of the fundus after a liquid 
meal. Using the gastric barostat, Tack and colleagues found that 43% of patients with 
medically refractory idiopathic gastroparesis had impaired FA [44]. In another study, 
scintigraphy of a solid meal was used to show that only 12% of patients in a mixed 
gastroparesis group had impaired FA [51]. However, impaired FA was found to be associated 
with non-diabetic gastroparesis.  
 
Visceral hypersensitivity 
A lowered threshold for sensing a mechanical or chemical stimulus (hypersensitivity), sensing 
the stimulus as painful at a lower threshold (hyperalgesia) or sensing an otherwise non-painful 
stimulus as painful (allodynia) is termed visceral hypersensitivity. The mechanisms behind 
visceral hypersensitivity is not fully understood. However, the vanilloid 1 receptor (TRPV1), 
an ion channel involved in a wide range of sensory functions, is assumed to play a central role 
in this process. In medically refractory idiopathic gastroparesis, Tack et al found visceral 
hypersensitivity to be present in 29% of the study subjects and this was associated with early 
satiety, abdominal pain and anorexia [44].  
 
Antropyloroduodenal motility and coordination 
A general antral hypomotility may be present in patients with idiopathic gastroparesis, in 
which frequency, velocity and amplitude of antral contractions is blunted and this may be one 
of the mechanisms leading to delayed gastric emptying [47, 52].  
 The endoluminal functional lumen imaging probe (EndoFLIP®, Crospon Ltd, Galway, 
Éire) uses impedance planimetry to measure multiple physiological characteristics of the 
pylorus, including its diameter, pressure and distensibility. Compared to healthy volunteers, 
distensibility seems to be decreased and pyloric pressure increased in a subset of idiopathic 
gastroparesis, though it is uncertain whether these parameters are associated with degree of 
gastric retention [53-55].  
 
Other motility dysfunctions 
Extragastric motility dysfunction appear to be a relatively common feature in idiopathic 
gastroparesis. Esophageal dysmotility and dysphagia may be predictive of delayed gastric 
emptying, and the two motility disorders seem to correlate with each other [56, 57]. Impaired 
small bowel and colonic motility has also been demonstrated in patients with idiopathic 
gastroparesis [47, 48, 58].  
 
Post-infectious gastroparesis 
A subgroup of patients with idiopathic gastroparesis has an onset of symptoms after a prior 
infection. Multiple infectious agents are assumed to be able to cause post-infectious 
gastroparesis including Epstein-Barr virus, cytomegalovirus and enterovirus [4, 59, 60]. An 
infectious prodrome with symptoms of food poisoning, gastroenteritis or upper respiratory 
infection is common [6]. Patients with post-infectious gastroparesis have been suggested to be 
associated with dysautonomia [60]. However, this has not been systematically studied. 
Clinically, post-infectious gastroparesis is similar to other patients with idiopathic 
gastroparesis but is associated with an acute onset of symptoms [4, 6]. Identifying patients 
with a presumed viral prodrome is important, as this may be associated with long term clinical 
improvement [4, 59, 61-63].  
 




There is a general lack of treatment studies specifically addressing patients with idiopathic 
gastroparesis. Therefore, treatment recommendations are largely based on the general 
principles of treatment of gastroparesis in general. Treatment involving minimal risk of side 
effects should be tried before more invasive options are considered, as shown in Table 1.  
In a prospective study of 262 gastroparesis patients (177 idiopathic), only one third responded 
with a modest symptomatic improvement after 48 weeks of standard care, which included 
medications (anti-emetics, prokinetics, proton pump inhibitors), total parenteral nutrition in 
Treatment ladder in idiopathic gastroparesis 
Dietary 
recommendations  
Food should be of small particle size, or easy to process into small 
particles.  Small, frequent meals accompanied by liquids to ease gastric 
emptying. Avoid meals containing high amounts of fats, fiber or other 
components known to slow gastric emptying. Dietary guidance may be 




Metoclopramide (10 mg, 10-15 minutes before a meal, preferably liquid 
formulation). Domperidone (10-20 mg x 3). Erythromycin (100-250 mg 
x 3, preferably liquid formulation). Ondansetron (4-8 mg before 




In cases refractory to medical therapy, one can consider placing a 
gastrostomy tube for decompression and a jejunostomy tube for enteral 
nutrition. In carefully selected patients, consider performing a 
pyloroplasty. As a last resort, total/subtotal gastrectomy may be 
performed. Gastric electrical stimulation is currently not advised for 
patients with idiopathic gastroparesis. 
26 patients and gastric electrical stimulation in 18 patients [63]. Symptomatic improvement 
has been found to be associated with male sex, initial infectious prodrome and age 50 years or 
older, while a lack of symptomatic improvement was associated with abdominal pain, 4-hour 
gastric retention greater than 20%, severe GERD, obesity and moderate to severe depression 
[63]. Tricyclic antidepressive medications may not have a place in the treatment of idiopathic 
gastroparesis, as in a placebo-controlled, double masked, randomized clinical trial, 
nortriptyline was not found to be superior to placebo [64]. 
 
Gastric electrical stimulation 
In gastroparesis patients refractory to medical treatment, some centers offer treatment with 
gastric electrical stimulation (GS) [65]. In a long-term study of both diabetic and idiopathic 
subjects, GS has been shown to near normalize serosal EGG parameters [66]. Though varying 
in the effect on gastric emptying, the device has shown efficacy in open label studies [65, 67-
76], but failed to show significant symptomatic improvement in idiopathic gastroparesis in 
double blinded, placebo-controlled studies [77, 78]. Most centers now only offers GS for 
patients with diabetic gastroparesis. 
 
Pyloric therapies 
As the pyloric muscle is believed to play a role in the pathophysiology of gastroparesis, 
multiple therapies targeting the pyloric sphincter have been developed. Injections with 
botulinum toxin A into the pyloric sphincter has shown mixed results on symptoms and 
gastric emptying in open label trials [79-81]. In randomized double blinded placebo-
controlled studies of patients with mixed etiology of gastroparesis, the effect was not superior 
to placebo [82, 83].  
 
Laparoscopic pyloroplasty is a safe and effective therapy to reduce gastric retention in 
patients with gastroparesis and seems to be effective in reducing symptoms [84]. Gastric per 
oral endoscopic myotomy (POP) is another promising treatment which can be used to cleave 
the pylorus [85]. In retrospective open label studies of mixed etiology gastroparesis cohorts, 
POP is safe and effective at reducing 4-hour GES and most symptoms of gastroparesis [85-
89]. In one study, POP was as effective as laparoscopic pyloroplasty (PP) at reducing 
symptoms and gastric emptying time, but resulted in less complications, a shorter length of 
hospital stay and had a shorter operation time [87]. As such, POP is a minimally invasive 
alternative to PP. However, as POP is a relatively new technique, long-term data on efficacy, 
side-effects and complications are not available. Further, randomized double blinded placebo-
controlled studies specifically targeting idiopathic gastroparesis are needed.  
 
Pyloric therapies in combination with GS may be more efficient than either therapy alone. In 
two studies of patients with gastroparesis, PP in combination with GES significantly 
improved symptoms better than patients only receiving GS or PP regardless of etiology [90, 
91]. However, both studies are limited by small sample size and a retrospective design.  
 
Individualized treatment 
GS for idiopathic gastroparesis is currently not recommended [2]. However, a novel approach 
to patient selection could be to utilize the knowledge of response to GS. Nausea/vomiting as a 
primary symptom seems to predict the best response to GS, while abdominal pain and 
bloating seem to be associated with poor symptomatic improvement [65, 70, 92, 93]. Severe 
ICC-depletion seems to be predictive of a negative symptomatic response to GS [12, 94]. In 
another study, response to GS was inversely correlated with number of ganglia per high-
power field [15]. However, endoscopic minimally invasive techniques for harvesting full-
thickness gastric wall biopsies need to be developed before this can be utilized in clinical 
practice.  
Since a subgroup of patients with idiopathic gastroparesis show objective signs of 
pathology in the pyloric sphincter, this could possibly be used to select patients for pyloric 
interventions. In one study, low pyloric distensibility was used as selection criteria for pyloric 
balloon dilation [55]. Low pyloric distensibility (< 9.2 mm2/mmHg) was also found to be 
predictive of clinical efficacy of POP in a pilot study, though only 4 of 20 patients had 
idiopathic gastroparesis [95]. Patients with normal slow wave activity on EGG may also be 
more responsive to pyloric botulinum toxin A injection or pyloric balloon dilation [96]. 
However, further studies are needed to identify parameters for use in such treatment 
algorithms.  
 
Novel medical treatment 
Intravenous immunoglobulin therapy (IVIG)  
Gastroparesis from autoimmune disorders may be considered one subgroup of idiopathic 
gastroparesis. In one case series, 14 patients with symptoms of gastroparesis refractory to 
medical and GS therapy were identified with immunological abnormalities on full-thickness 
gastric biopsies and on an autoimmune serological panel [97]. The study subjects were then 





In one case study, 9 of 11 patients with post-infectious gastroparesis, an active enterovirus 
infection was observed in gastric biopsies [60]. Eight of these were treated with anti-viral 
medications and/or immune therapies such as IVIG with most of the patients experiencing 




Although serotonin has been shown to play a role in the motor and sensory functions of the 
upper gastrointestinal tract, only minor serotonergic alterations has been found in idiopathic 
gastroparesis [98]. However, as the now withdrawn 5-HT4 agonist cisapride was shown to 
increase gastric emptying [99], there is a search for new, equally effective 5-HT4 agonists. 
Prucalopride is a 5-HT4 agonist, which is approved for the treatment of chronic constipation 
in most countries and is used in the treatment of gastroparesis at some centers. The effect of 
this agent in idiopathic gastroparesis has been assessed in a completed double-blinded cross-
over study, but results await publication [100]. Other agents under investigation includes 
velusetrag, which has completed phase I and phase II studies [101, 102], and TAK-954 [103].  
 
Ghrelin agonists 
Ghrelin is a peptide hormone mainly involved in appetite regulation. Amongst several 
mechanisms, it can act as a stimulant on gastrointestinal motility. The ghrelin agonist 
relamorelin is a promising new drug shown to be safe and effective at reducing gastroparesis 
symptoms in a randomized, placebo-controlled study of 393 diabetic gastroparesis patients 
[104]. However, the effect of ghrelin agonists on idiopathic gastroparesis has not been 
extensively studied in a systematic manner. An exception is one double-blinded, placebo-
controlled study of 6 patients, in which 40 µg ghrelin was infused intravenously at the start of 
a meal [105]. The study subjects experienced improvement in the cumulative meal-related 
symptom score, fullness and pain. Liquid gastric emptying was also significantly enhanced 
and tended to correlate with improvement in bloating (P=0.06). This could be of importance, 
as a delay in liquid gastric emptying may be more common in non-diabetic than diabetic 
gastroparesis. As ghrelin-release in response to sham feeding seem to be normal in idiopathic 
gastroparesis, the manner through which ghrelin mediates improvement in motility and 
symptoms is unclear [106]. However, the authors suggests that one mechanism may be 
through increased fundic accommodation as this is shown in healthy subjects given ghrelin. 
As impaired fundic accommodation is found in a subset of patients with idiopathic 
gastroparesis, ghrelin analogues could represent a new treatment alternative in idiopathic 
gastroparesis, but this demands confirmation in larger studies. 
 
Anti-emetics 
Symptoms of nausea and vomiting in gastroparesis can be treated with anti-emetics, as listed 
in table 1. However, prolonged use of metoclopramide may lead to irreversible tardive 
dyskinesia. Domperidone use bears a risk of cardiac arrhythmia and sudden cardiac death, 
while the effect of ondansetron on nausea in gastroparesis has not been studied specifically. 
As such, there is a need for new anti-emetic medications for patients with gastroparesis.  
The neurokinin 1 (NK1) receptor is central in both the acute and delayed emetic 
process and distributed both peripherally in the gastrointestinal tract and centrally in the 
vomiting center in the brainstem. As such, NK-1 antagonists have been developed for the 
treatment of delayed emesis in chemotherapy-induced nausea and vomiting. NK1-antagonists 
may have a role in the treatment of idiopathic gastroparesis, as in a double-blind, placebo-
controlled study of patients with gastroparesis or associated conditions, the NK1-antagonist 
aprepitant was found to have moderate effects on nausea, vomiting and overall symptoms 
[107]. However, the primary aim of the study, to decrease nausea 25 mm or more on a 100 
mm visual analogue scale, was not met.  
TAK-906, a peripheral dopamine D2/D3 receptor antagonist, likely ameliorates nausea 
and vomiting in a similar manner as domperidone, but hopefully without the cardiac side 
effects. Phase I is completed, while phase II-studies are ongoing [103, 108].  
 Systematically studied medications for the treatment of gastroparesis exacerbations is 
also lacking. However, in a double-blind study, Haloperidol, a dopamine receptor antagonist 
antipsychotic drug, was more effective than placebo as an adjunctive therapy to treat 
gastroparesis exacerbations in an emergency department [109].  
 Olanzapine is another antipsychotic medication that may be effective in the treatment 
of gastroparesis. In an ongoing pilot study, it is hypothesized to have an anti-emetic and 
prokinetic effect on gut motility, partially through increased ghrelin levels [110].  
 
Others 
Trials utilizing vagal stimulation are ongoing in mixed gastroparesis cohorts. Though largely 
unexplored in gastroparesis, low vagal tone may lead to inflammation and gastrointestinal 
dysmotility. Therefore, vagal stimulation may be a novel way of increasing gastric emptying 
and perhaps shifting the gastric muscularis macrophage population to a phenotypically anti-
inflammatory one [111, 112].  
As multiple motility dysfunctions and symptoms of idiopathic gastroparesis are shared 
with functional dyspepsia, medication such as acotiamide used to treat functional dyspepsia 




In addition to delayed gastric emptying, patients with idiopathic gastroparesis can suffer from 
multiple other motility dysfunctions, gastric dysrhythmia and visceral hypersensitivity. All of 
these may stem from underlying cellular alterations. Current treatment is limited to alleviating 
symptoms, but as novel pathophysiological features are uncovered, development of new 
treatment modalities should aim to normalize or modulate immune alterations, sensory 
pathways, gastric myoelectrical activity and the affected cell types involved. In addition, there 
are need for further research to better select patients to existing advanced treatments such as 
gastric neurostimulation or pyloric interventions.  
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